Open AccessWhich Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study
Author(s) -
Beibei Shi,
Xuelian Zhang,
Haiqing Zhu,
Ying Shi,
Xiaoyan Xing,
Wenying Yang
Publication year - 2017
Publication title -
diabetes therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.907
H-Index - 33
ISSN - 1869-6961
DOI - 10.1007/s13300-017-0284-1
Subject(s) - medicine , glycated hemoglobin , insulin glargine , diabetes mellitus , body mass index , logistic regression , clinical endpoint , insulin , type 2 diabetes , population , subgroup analysis , type 2 diabetes mellitus , confidence interval , hypoglycemia , endocrinology , clinical trial , environmental health
This subgroup analysis of data from the 16-week Lantus Registry Study in China investigated the characteristics of patients with type 2 diabetes mellitus (T2DM) associated with clinical benefits of transitioning therapy from premixed insulin to insulin glargine (100 U/ml) plus oral antidiabetic drugs (OADs).